HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesScenario AnalysisRegulatoryStrategyInsightsPricing

Workspace

Workspace

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval83% confidence

Competitive Generic Therapy Approvals

Source: FDA

Why This Matters

Why this matters: sets a approval precedent in the same sub-indication (asthma) as Breztri Gains US Approval as First Triple Therapy for Asthma.

Regulatory Analysis

Explore the FDA’s Competitive Generic Therapy Approvals page, offering insights into the program designed to encourage generic drug competition. Access information about approved CGT products and find resources, including a downloadable CGT approvals spreadsheet.

Supporting Context

Therapeutic area
Respiratory · Asthma
Sub-indication
Asthma

Related signal: Breztri Gains US Approval as First Triple Therapy for Asthma

Source

View source document

Related Signal

Open signal — Breztri Gains US Approval as First Triple Therapy for Asthma
PrivacyTermsRefund PolicyDisclaimer

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.